行情

SONN

SONN

Sonnet BioTherapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

0.3140
-0.0090
-2.79%
盘后: 0.3169 +0.0029 +0.92% 19:29 01/24 EST
开盘
0.3133
昨收
0.3230
最高
0.3199
最低
0.2900
成交量
129.08万
成交额
--
52周最高
3.415
52周最低
0.2900
市值
1,891.87万
市盈率(TTM)
-0.2828
分时
5日
1月
3月
1年
5年
15 Stocks Moving in Monday's Pre-Market Session
Gainers IceCure Medical Ltd (NASDAQ: ICCM) rose 36.5% to $3.89 in pre-market trading. IceCure Medical, last week, received notice of intention to grant a European patent covering its cryogenic pump.
Benzinga · 2021/12/27 11:17
We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 2021/12/20 17:58
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $2.5
Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and lowers the price target from $8 to $2.5.
Benzinga · 2021/12/20 13:34
25 Stocks Moving in Monday's Pre-Market Session
Gainers Society Pass Incorporated (NASDAQ: SOPA) rose 68% to $5.59 in pre-market trading after the company reported addition to the Russell 2000 Index.
Benzinga · 2021/12/20 11:35
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 2021/12/17 12:54
Sonnet BioTherapeutics EPS beats by $0.02
Sonnet BioTherapeutics (NASDAQ:SONN): FY GAAP EPS of -$1.02 beats by $0.02. Revenue of $0.48M Press Release As of September 30, 2021, Sonnet had $27.6M cash on hand. Jay Cross, CFO
Seekingalpha · 2021/12/17 11:37
Sonnet BioTherapeutics Files 10-K
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001106838/000149315221031781/form10-k.htm
Benzinga · 2021/12/17 11:32
Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update
PRINCETON, NJ / ACCESSWIRE / December 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the fisca...
ACCESSWIRE · 2021/12/17 11:30
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解SONN最新的财务预测,通过SONN每股收益,每股净资产,每股现金流等数据分析Sonnet BioTherapeutics Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

33.33%强力推荐
66.67%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测SONN价格均价为3.167,最高价位5.00,最低价为2.000。
最高5.00
均价3.167
最低2.000
现价0.3140
EPS
实际EPS
预期EPS
-0.27-0.20-0.14-0.07
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
机构持股
总机构数: 26
机构持股: 300.72万
持股比例: 4.99%
总股本: 6,025.06万
类型机构数股数
增持
5
155.67万
建仓
5
17.96万
减持
1
844
平仓
2
1,001
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-1.15%
制药与医学研究
-0.55%
高管信息
Chairman/President/Chief Executive Officer/Director
Pankaj Mohan
Chief Financial Officer/Treasurer/Secretary
John Cross
Chief Technology Officer
Susan Dexter
Chief Scientific Officer
John Cini
Other
Manuel Dafonseca
Other
Richard Kenney
Director
Donald Griffith
Independent Director
Nailesh Bhatt
Independent Director
Albert Dyrness
Independent Director
Raghu Rao
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
SONN 简况
Sonnet BioTherapeutics Holdings Inc是一家临床阶段的生物制药公司。该公司的技术,即完全人白蛋白结合(FHAB)有助于开发生物药物。FHAB利用与一个或两个能够影响单一或双特异性作用机制的治疗分子连接的全人单链抗体片段。FHAB构建体包含一个结构域,该结构域旨在与人血清白蛋白结合并使其上升,以转运至目标,例如实体瘤或淋巴系统。它设计的结构是为了改善特定组织中的药物积累,并延长体内活动的持续时间。FHAB开发候选物是在哺乳动物细胞培养物中产生的,这可以实现糖基化,从而降低免疫原性的风险。FHAB技术可以帮助开发一系列人类疾病领域的药物,包括肿瘤、自身免疫、致病、炎症和血液病。

微牛提供Sonnet Biotherapeutics Holdings Inc(NASDAQ-SONN)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的SONN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易SONN股票基本功能。